Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Apr 19;6(4):e784. doi: 10.1038/tp.2016.51

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Macmillan Publishers Limited

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Effects of drugs on ongoing electrophysiological activity in the ketamine experiment. (a) Heat maps of drug effects on spectral power over time. The two red vertical lines represent the injection of the test drug at t=20, and of ketamine at t=45 min. Quantification of the effects of drugs on average gamma power following the injection of ketamine, relative to the pre-injection period (b). Similar to the MK801 study, ketamine elevates ongoing gamma power, but this was significantly reduced by pretreatment with HAL, CLOZ and OLANZ. (c) These effects are also evident when visualizing the effect of pretreatments over the time course of the experiment. ^####P<0.0001 represents the significant difference between vehicle and ketamine; ***P<0.001, ****P<0.0001 represent the significant difference between test drug+ketamine and vehicle+ketamine groups. CLOZ, clozapine; HAL, haloperidol; KET, ketamine; OLANZ, olanzapine.